Abstract
Traumatic brain injury (TBI) imposes horrendous neurophysiological alterations leading to most devastating forms of neuro-disability. Which includes impaired cognition, distorted locomotors activity and psychosomatic disability in both youths and adults. Emerging evidence from recent studies has identified mesenchymal stem cells (MSCs) as one of the promising category of stem cells having excellent neuroregenerative capability in TBI victims. Some of the clinical and animal studies reported that MSCs transplantation could cure neuronal damage as well as improve cognitive and locomotors behaviors in TBI. However, mechanism behind their broad spectrum neuroregenerative potential in TBI has not been reviewed yet. Therefore, in the present article, we present a comprehensive data on the important attributes of MSCs, such as neurotransdifferentiation, neuroprotection, axonal repair and plasticity, maintenance of blood-brain integrity, reduction of reactive oxygen species (ROS) and immunomodulation. We have reviewed in detail the crucial neurogenic capabilities of MSCs in vivo and provided consolidated knowledge regarding their cellular remodeling in TBI for future therapeutic implications.
Keywords: Immunomodulation and therapeutic, mesenchymal stem cells, neuro-transdifferentiation, traumatic brain injury.
Current Stem Cell Research & Therapy
Title:Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury
Volume: 11 Issue: 2
Author(s): Soumya Pati, Sangu Muthuraju, Raisah Ab. Hadi, Tee Jong Huat, Shailja Singh, Mirjana Maletic-Savatic, Jafri Malin Abdullah and Hasnan Jaafar
Affiliation:
Keywords: Immunomodulation and therapeutic, mesenchymal stem cells, neuro-transdifferentiation, traumatic brain injury.
Abstract: Traumatic brain injury (TBI) imposes horrendous neurophysiological alterations leading to most devastating forms of neuro-disability. Which includes impaired cognition, distorted locomotors activity and psychosomatic disability in both youths and adults. Emerging evidence from recent studies has identified mesenchymal stem cells (MSCs) as one of the promising category of stem cells having excellent neuroregenerative capability in TBI victims. Some of the clinical and animal studies reported that MSCs transplantation could cure neuronal damage as well as improve cognitive and locomotors behaviors in TBI. However, mechanism behind their broad spectrum neuroregenerative potential in TBI has not been reviewed yet. Therefore, in the present article, we present a comprehensive data on the important attributes of MSCs, such as neurotransdifferentiation, neuroprotection, axonal repair and plasticity, maintenance of blood-brain integrity, reduction of reactive oxygen species (ROS) and immunomodulation. We have reviewed in detail the crucial neurogenic capabilities of MSCs in vivo and provided consolidated knowledge regarding their cellular remodeling in TBI for future therapeutic implications.
Export Options
About this article
Cite this article as:
Pati Soumya, Muthuraju Sangu, Ab. Hadi Raisah, Jong Huat Tee, Singh Shailja, Maletic-Savatic Mirjana, Malin Abdullah Jafri and Jaafar Hasnan, Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury, Current Stem Cell Research & Therapy 2016; 11 (2) . https://dx.doi.org/10.2174/1574888X10666151019120050
DOI https://dx.doi.org/10.2174/1574888X10666151019120050 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Experimental Model Considerations for the Study of Protein-Energy Malnutrition Co-Existing with Ischemic Brain Injury
Current Neurovascular Research Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Rationale of Hyperbaric Oxygenation in Cerebral Vascular Insult
Current Vascular Pharmacology Peripartum Cardiomyopathy: An Intensivist's Perspective
Current Women`s Health Reviews Gyroxin and Its Biological Activity: Effects on CNS Basement Membranes and Endothelium and Protease-Activated Receptors
Current Medicinal Chemistry Targeting Mitochondrial Biogenesis to Treat Insulin Resistance
Current Pharmaceutical Design Proteomic Analysis of Neutrophil Priming by PAF
Protein & Peptide Letters Shut-Down of Translation, a Global Neuronal Stress Response:Mechanisms and Pathological Relevance
Current Pharmaceutical Design Patent Selections
Recent Patents on Biotechnology Integrative Neurochemistry and Neurobiology of Social Recognition and Behavior Analyzed with Respect to CD38-Dependent Brain Oxytocin Secretion
Current Topics in Medicinal Chemistry Brain Injury Associated with Widely Abused Amphetamines: Neuroinflammation, Neurogenesis and Blood-Brain Barrier
Current Drug Abuse Reviews Dopamine Administration in Very Low Birth Weight Preterm Infants:Emerging Issues on Endocrine Effects
Current Pediatric Reviews Glycogen Synthase Kinase-3: A Potential Target for Drug Discovery in the Treatment of Neurodegenerative Disorders
Current Enzyme Inhibition GCPII Imaging and Cancer
Current Medicinal Chemistry